The DOI matches its Crossref record; 211 of the 211 references it cites were found in a registry or an index.
Autocrine and paracrine purinergic signaling in the most lethal types of cancer
Open accessAbstract
Cancer comprises a collection of diseases that occur in almost any tissue and it is characterized by an abnormal and uncontrolled cell growth that results in tumor formation and propagation to other tissues, causing tissue and organ malfunction and death. Despite the undeniable improvement in cancer diagnostics and therapy, there is an urgent need for new therapeutic and preventive strategies with improved efficacy and fewer side effects. In this context, purinergic signaling emerges as an interesting candidate as a cancer biomarker or therapeutic target. There is abundant evidence that tumor cells have significant changes in the expression of purinergic receptors, which comprise the G-protein coupled P2Y and AdoR families of receptors and the ligand-gated ion channel P2X receptors. Tumor cells also exhibit changes in the expression of nucleotidases and other enzymes involved in nucleotide metabolism, and the concentrations of extracellular nucleotides are significantly higher than those observed in normal cells. In this review, we will focus on the potential role of purinergic signaling in the ten most lethal cancers (lung, breast, colorectal, liver, stomach, prostate, cervical, esophagus, pancreas, and ovary), which together are responsible for more than 5 million annual deaths.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“As observed in other tumors [131], the ADO signaling pathways may regulate MPM cells–TAMs interaction, inducing TAMs’ proliferation and the release of pro-tumoral cytokines [129].”
From Chronic Inflammation, Oxidative Stress and Metabolic Plasticity: Three Players Driving the Pro-Tumorigenic Microenvironment in Malignant Mesothelioma (2023) · cites this paper as [129]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“While under normal conditions the Adenosinergic Pathway (AP) is fine-tuned and controlled, in cancer the signaling is altered, promoting malignant cell transformation. AP in cancer cells by increasing the secretion of cytokines and immune modulatory factors, including IL6, IL10, TGFβ, and VEGF, and activating survival/signaling pathways such as PI3K-Akt-mTOR, sustains immunosuppression and”
From Chronic Inflammation, Oxidative Stress and Metabolic Plasticity: Three Players Driving the Pro-Tumorigenic Microenvironment in Malignant Mesothelioma (2023) · cites this paper as [129]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012
Ferlay, J., Soerjomataram, I., Dikshit, R., Eser, S., Mathers, C., Rebelo, M., Parkin, D. M., Forman, D., & Bray, F. (2015) · International Journal of Cancer · doi:10.1002/ijc.29210 · Cited by 28,766
(1996) · Institutional Research Information System University of Turin (University of Turin) · doi:10.1111/j · Cited by 5,486
Smyth, E. C., Nilsson, M., Grabsch, H. I., van Grieken, N. C., & Lordick, F. (2020) · The Lancet · doi:10.1016/s0140-6736(20)31288-5 · Cited by 4,803
Lung cancer: current therapies and new targeted treatments
Hirsch, F. R., Scagliotti, G. V., Mulshine, J. L., Kwon, R., Curran, W. J., Wu, Y.-L., & Paz-Ares, L. (2017) · The Lancet · doi:10.1016/s0140-6736(16)30958-8 · Cited by 3,283
Apetoh, L., Ghiringhelli, F., Tesniere, A., Obeid, M., Ortiz, C., Criollo, A., Mignot, G., Maiuri, M. C., Ullrich, E., Saulnier, P., et al. (2007) · Nature Medicine · doi:10.1038/nm1622 · Cited by 3,056
Lheureux, S., Gourley, C., Vergote, I., & Oza, A. M. (2019) · The Lancet · doi:10.1016/s0140-6736(18)32552-2 · Cited by 1,919
Humphrey, P. A., Moch, H., Cubilla, A. L., Ulbright, T. M., & Reuter, V. E. (2016) · European Urology · doi:10.1016/j.eururo.2016.02.028 · Cited by 1,916
Ghiringhelli, F., Apetoh, L., Tesniere, A., Aymeric, L., Ma, Y., Ortiz, C., Vermaelen, K., Panaretakis, T., Mignot, G., Ullrich, E., et al. (2009) · Nature Medicine · doi:10.1038/nm.2028 · Cited by 1,898
Colombo, M., Moita, C., van Niel, G., Kowal, J., Vigneron, J., Benaroch, P., Manel, N., Moita, L. F., Théry, C., & Raposo, G. (2013) · Journal of Cell Science · doi:10.1242/jcs.128868 · Cited by 1,463
Revisiting the hallmarks of cancer.
Fouad, Y. A., & Aanei, C. M. (2017) · Europe PMC (PubMed Central) · Cited by 1,245
Cited by
A Single‐Cell Metabolic Profiling Characterizes Human Aging via SlipChip‐SERS
Liu, F., Liu, J., Luo, Y., Wu, S., Liu, X., Chen, H., Luo, Z., Yuan, H., Shen, F., Zhu, F., et al. (2024) · Advanced Science · doi:10.1002/advs.202406668 · Cited by 48
Xu, H., Dong, C., Xiang, T., Shentu, X., Yu, Z., Jiang, X., Yu, J., Ma, D., & Xie, Y. (2024) · Journal of Hazardous Materials · doi:10.1016/j.jhazmat.2024.136656 · Cited by 47
Interplay between purinergic signalling and extracellular vesicles in health and disease
Carotti, V., Rigalli, J. P., van der Wijst, J., & Hoenderop, J. G. J. (2022) · Biochemical Pharmacology · doi:10.1016/j.bcp.2022.115192 · Cited by 42
Mesothelioma Malignancy and the Microenvironment: Molecular Mechanisms
Cersosimo, F., Barbarino, M., Lonardi, S., Vermi, W., Giordano, A., Bellan, C., & Giurisato, E. (2021) · Cancers · doi:10.3390/cancers13225664 · Cited by 41
Fiorilla, I., Martinotti, S., Todesco, A. M., Bonsignore, G., Cavaletto, M., Patrone, M., Ranzato, E., & Audrito, V. (2023) · Cells · doi:10.3390/cells12162048 · Cited by 39
Metadata
- Authors
- Reyna-Jeldes, M., Díaz-Muñoz, M., Madariaga, J. A., Coddou, C., & Vázquez-Cuevas, F. G.
- Affiliations
- Universidad Católica del Norte (CL)
- Corresponding author
- Coddou, C.
- Venue
- Purinergic Signalling
- Published
- 2021-05-12
- Volume
- 17
- Issue
- 3
- Pages
- 345-370
- ISSN
- 1573-9538 (ISSN-L)
- 1573-9546
- PMC
- PMC8410929
- OpenAlex
- W3160609839
- Cited by
- 25
- References
- 206
- Citations by year
- 2026: 1 · 2025: 2 · 2024: 6 · 2023: 7 · 2022: 5 · 2021: 4
- FWCI
- 0.86
- Type
- journal article
- Language
- en
- Open access
- green
- europepmc.org
- Licence
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
- Locations
- Purinergic Signalling (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Dirección General de Asuntos del Personal Académico, Universidad Nacional Autónoma de México (IN202620, IN202121)
- Consejo Nacional de Ciencia y Tecnología (284557)
- Fondo Nacional de Desarrollo Científico y Tecnológico (11614)
- Programa de Equipamiento Científico y Tecnológico, Chile (EQM140100)
- Millennium Nucleous for the Study of Pain
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Physiology › Adenosine and Purinergic Signaling
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Biochemical and Molecular Research
- Health Sciences › Medicine › Nephrology › Gout, Hyperuricemia, Uric Acid
- Keywords
- purinergic signaling, autocrine signaling, paracrine signaling, purinergic receptors, P2Y receptors, adenosine receptors, P2X receptors, nucleotidase, extracellular nucleotides, nucleotide metabolism, tumor markers, cancer therapy targets, lung cancer, breast cancer, colorectal cancer, liver cancer, gastric cancer, prostate cancer, cervical cancer, esophageal cancer, pancreatic cancer, ovarian cancer
- MeSH terms
- Adenosine Triphosphate, Animals, Humans, Neoplasms, Receptors, Purinergic, Signal Transduction, Autocrine Communication, Paracrine Communication
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Autocrine and paracrine purinergic signaling in the most lethal types of cancer. https://app.cochat.ai/papers/10.1007/s11302-021-09785-8
- The paper
- Reyna-Jeldes, M., Díaz-Muñoz, M., Madariaga, J. A., Coddou, C., & Vázquez-Cuevas, F. G. (2021). Autocrine and paracrine purinergic signaling in the most lethal types of cancer. Purinergic Signalling. https://doi.org/10.1007/s11302-021-09785-8
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.